NeoGenomics (NEO) Competitors

NeoGenomics (NASDAQ:NEO) and Concentrix (NASDAQ:CNXC) are both business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Which has more risk & volatility, NEO or CNXC?

NeoGenomics has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Comparatively, Concentrix has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Does the media prefer NEO or CNXC?

In the previous week, NeoGenomics had 1 more articles in the media than Concentrix. MarketBeat recorded 9 mentions for NeoGenomics and 8 mentions for Concentrix. Concentrix's average media sentiment score of 1.54 beat NeoGenomics' score of 0.30 indicating that Concentrix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeoGenomics	0 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Concentrix	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Do analysts rate NEO or CNXC?

NeoGenomics currently has a consensus price target of $12.75, indicating a potential upside of 105.31%. Concentrix has a consensus price target of $66.75, indicating a potential upside of 38.51%. Given NeoGenomics' higher probable upside, equities research analysts plainly believe NeoGenomics is more favorable than Concentrix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeoGenomics	0 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Concentrix	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Do insiders & institutionals have more ownership in NEO or CNXC?

98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 90.3% of Concentrix shares are owned by institutional investors. 2.4% of NeoGenomics shares are owned by insiders. Comparatively, 3.2% of Concentrix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Is NEO or CNXC more profitable?

Concentrix has a net margin of 2.54% compared to NeoGenomics' net margin of -15.10%. Concentrix's return on equity of 16.31% beat NeoGenomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeoGenomics	-15.10%	-2.72%	-1.54%
Concentrix	2.54%	16.31%	5.56%

Which has higher earnings and valuation, NEO or CNXC?

Concentrix has higher revenue and earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Concentrix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeoGenomics	$660.57M	1.21	-$78.73M	-$0.81	-7.67
Concentrix	$9.62B	0.32	$251.22M	$3.64	13.24

Summary

Concentrix beats NeoGenomics on 11 of the 17 factors compared between the two stocks.